with the antiprogesterone agent mifepristone. Journal of Neurosurgery 74:861-866, 1991.

Klijn, J.G.M., de Jong, F.H., Bakker, G.H., et al. Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Research 49:2851–2856, 1989.

Konagaya, M., Bernard, P.A., and Max, S.R. Blockage of glucocorticoid receptor binding and inhibition of dexamethasone-induced muscle atrophy in the rat by RU 38486, a potent glucocorticoid antagonist. Endocrinology 119:375–380, 1986.

Lamberts, S.W., Koper, J.W., and de Jong, F.H. The endocrine effects of long-term treatment with mifepristone (RU 486). Journal of Clinical Endocrinology and Metabolism 73:187–191, 1991.

Nieman, L.K., Chrousos, G.P., Kellner, C., et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. Journal of Clinical Endocrinology and Metabolism 61:536–540, 1985.

Regelson, W., Loria, R., and Kalimi, M. Beyond "abortion": RU 486 and the needs of the crisis constituency. Journal of the American Medical Association 264:1026–1027, 1990.

Spitz, I.M., and Bardin, C.W. Clinical pharmacology of RU 486—An antiprogestin and antiglucocorticoid. Contraception, in press (also see: RU 486—A modulator of progestin and glucocorticoid action. New England Journal of Medicine, in press).

The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement